Mizuho Downgrades Adverum Biotechnologies Price Target

Summary

Mizuho Securities has lowered the target price of Adverum Biotechnologies (NASDAQ: ADVM) from $16.00 to $12.00, maintaining an ‘outperform’ rating. This suggests a potential increase of 384.85% from the previous day’s closing price. Other analysts have differing views, with HC Wainwright and Chardan Capital setting higher targets of $30.00 and $33.00, respectively. Adverum’s stock fell to $2.48, with a market cap of $51.7 million. The company recently reported a loss of $1.96 per share in its latest financial report.Market Beat

Impact Analysis

The event is at the company level, specifically impacting Adverum Biotechnologies due to a revised target stock price by Mizuho Securities. The ‘outperform’ rating suggests optimism despite the lowered price target, indicating potential future growth which may attract investors looking for high-risk, high-reward opportunities. The market reaction, reflected in the stock’s decline to $2.48, highlights current investor uncertainty or skepticism, potentially driven by recent financial losses. Investors may see mixed signals, with other analysts’ higher targets suggesting possible undervaluation. Risks include continued financial losses, while opportunities might lie in potential recovery and alignment with analyst expectations. Investors should carefully consider these factors, noting the variance in analyst opinions.Market Beat+ 2